Editas Medicine, Inc. (EDIT) Q4 2023 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Editas Medicine, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.029 -- 00:00:05.271 Good morning and welcome to Editas Medicine's fourth quarter and full year 2023 conference 00:00:05.271 -- 00:00:08.972 call. All participants are now in a listen-only mode. 00:00:08.972 -- 00:00:12.153 There will be a question and answer session at the end of this call. 00:00:12.153 -- 00:00:16.254 Please be advised that this call is being recorded at the company's request. 00:00:16.254 -- 00:00:20.055 I would now like to turn the call over to Christy Barnett, Corporate Communications and 00:00:20.055 -- 00:00:23.756 Investor Relations at Editas Medicine. 00:00:24.317 -- 00:00:29.255 Thank you, Maria. Good morning, everyone, and welcome to our fourth quarter and full 00:00:29.255 -- 00:00:31.196 year 2023 conference 00:00:31.196 -- 00:00:36.599 call. Earlier this morning, we issued a press release providing our financial results 00:00:36.599 -- 00:00:41.902 and recent corporate updates. A replay of today's call will be available in the investors 00:00:41.902 -- 00:00:46.785 section of our website approximately two hours after its completion. 00:00:46.785 -- 00:00:51.127 After our prepared remarks, we will open the call for Q&A. 00:00:51.135 -- 00:00:55.579 As a reminder, various remarks that we make during this call about the company's future 00:00:55.579 -- 00:01:00.643 expectations, plans, and prospects constitute forward-looking statements for the 00:01:00.643 -- 00:01:06.067 purposes of the safe harbor provisions under the Private Securities Litigation Reform 00:01:06.067 -- 00:01:08.357 Act of 1995. 00:01:08.509 -- 00:01:13.833 Actual results may differ materially from those indicated by these forward-looking statements 00:01:13.833 -- 00:01:19.272 as a result of various important factors including those discussed in the risk...